Mouser Electronics Announces Partnership with DS PENSKE for Formula E Season 11 with Debut in Brazil

3.12.2024 17:09:00 CET | Business Wire | Press release

Mouser Electronics, Inc., the New Product Introduction (NPI) leader™ empowering innovation, is gearing up to sponsor the DS PENSKE Formula E racing team as they begin Season 11 at the Sambadrome in São Paulo, Brazil, on December 7. Mouser is sponsoring the team throughout the 2024/2025 ABB FIA Formula E World Championship racing season in collaboration with TTI, Inc. and valued manufacturers Molex and KYOCERA AVX.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203326874/en/

This is the first time that Brazil has hosted the Formula E season-opener, and the race will see two-time Formula E World Champion Jean-Éric Vergne joined by Maximilian Günther as they pilot the new GEN3 Evo car. The GEN3 Evo is faster, stronger, and more agile than its predecessors and features an aggressive new body kit designed to be stronger, more robust and more aerodynamic. It also allows for all-wheel drive, a first for a Formula E car.

"Mouser is thrilled to continue our support of the DS PENSKE Formula E team," said Todd McAtee, Senior Vice President, Business Development for Mouser Electronics. "We're also excited to see what the new car can do. With acceleration 0-60mph, 30% faster than a current F1 car, this is sure to be an exhilarating season."

"TTI is pleased to team up again with Mouser to support DS PENSKE and promote this dynamic sport and its commitment to innovation and environmental responsibility," said Mike Morton, TTI Chief Executive Officer. "We will be looking forward to a winning year ahead."

"The new car promises to continue the evolution of Formula E and serves as a powerful showcase for the electric future of motorsports," said Fred Bell, Molex Vice President of Global Distribution. "Mouser and Molex have been proud supporters since the inception of Formula E, and we wish the DS PENSKE team a safe and successful season."

"We're delighted to collaborate with Mouser and TTI in our partnership with the DS PENSKE Formula E racing team for another exciting season," said Alex Schenkel, KYOCERA AVX Senior Vice President of Global Sales.

Formula E will complete a 16-race season spanning ten iconic venues as it continues to pioneer all-electric racing. The globe-trotting schedule includes a return to Miami, Florida, double-headers in Tokyo and Monaco, and Formula E's first-ever trip to Jeddah in Saudi Arabia. A double-header finale in London, England, rounds out the largest Formula E race calendar to date.

Formula E cars are powered solely by electricity and represent a vision for the future of the motorsports industry, serving as a framework for research and development around zero-emission motoring. Racing is all about speed and endurance, and racing partnerships are an innovative way for Mouser to communicate its performance-driven business model and promote the newest technologies from its manufacturer partners.

To learn more about the Mouser-backed DS PENSKE Formula E racing team and view the Formula E schedule, visit https://www.mouser.com/formula-e/.

For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.

As a global authorized distributor, Mouser offers the widest selection of the newest semiconductors, electronic components and industrial automation products. Mouser's customers can expect 100% certified, genuine products that are fully traceable from each of its manufacturer partners. To help speed customers' designs, Mouser's website hosts an extensive library of technical resources, including a Technical Resource Center, along with product data sheets, supplier-specific reference designs, application notes, technical design information, engineering tools and other helpful information.

Engineers can stay abreast of today's exciting product, technology and application news through Mouser's complimentary e-newsletter. Mouser's email news and reference subscriptions are customizable to the unique and changing project needs of customers and subscribers. No other distributor gives engineers this much customization and control over the information they receive. Learn about emerging technologies, product trends and more by signing up today at https://sub.info.mouser.com/subscriber/.

About Mouser Electronics
Mouser Electronics is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 6.8 million products from over 1,200 manufacturer brands. Mouser offers 28 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 650,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/.

Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241203326874/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom